Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Kiniksa's 61.47 P/E ratio towers well above pharma peers while the stock trades at its 52-week high with an RSI of 73.2—a textbook overbought setup. The $4.5B market cap company is pricing in substantial growth expectations, yet the 10.8% short interest suggests meaningful skepticism persists among bearish players. This combination creates squeeze tension: if sentiment shifts, the extended valuation and crowded technical condition could spark sharp drawdowns, while a positive catalyst might ignite short-covering rallies given the elevated short position relative to float.